Skip to main content
Premium Trial:

Request an Annual Quote

Roche Dx Licenses Multilyte’s Multiparameter Binding Assay IP

NEW YORK (GenomeWeb News) - Roche Diagnostics today said it has signed a licensing agreement with Multilyte for access to Multilyte's patents for diagnostic assays.
 
Roche will pay a license fee and royalties from the sale of products covered by Multilyte’s patents.
 
Assays covered under the patents include mulitparameter binding assays, including immunoassays, to enable “simultaneous detection and analysis of many different analytes in small test samples of biological origin,” Roche said.
 
Roche said that the agreement will enable it to develop microarray-based immunoassays and other binding assay systems that will detect multiple analytes in a single reaction.
 
Multilyte was founded in 1988 as a spin-off from University College London by UCL biophysics professor Roger Ekins.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.